Simvastatin treatment reduces heat shock protein 60, 65, and 70 antibody titers in dyslipidemic patients: A randomized, double-blind, placebo-controlled, cross-over trial

Clinical Biochemistry

Volumn 44, Issue 2-3, 2011, Pages 192-197

  Moohebati, Mohsen ^a,b   Bidmeshgi, Shirin ^a   Azarpazhooh, Mahmoud R ^c   Daloee, Mahdi Hassanzadeh ^a,b   Ghayour Mobarhan, Majid ^a,b   Tavallaie, Shima ^a   Amini, Maral ^a,d   Momenzadeh, Akram ^b   Sahebkar, Amirhossein ^a   Paydar, Roghayeh ^a   Rahsepar, Amir A ^a,b   Parizadeh, Seyyed M R ^b   Akhlaghi, Saeed ^b   Ferns, Gordon A A ^e  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c Faculty of Sciences   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e KEELE UNIVERSITY   (United Kingdom)

Author keywords

Antibody; C reactive protein; Cross over study; Heat shock protein; Simvastatin

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEAT SHOCK PROTEIN 60; HEAT SHOCK PROTEIN 65; HEAT SHOCK PROTEIN 70; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; IMMUNOGLOBULIN G; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; CHAPERONIN 60; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ANTHROPOMETRY; ANTIBODY TITER; ARTICLE; ATHEROGENESIS; AUTOIMMUNITY; BLOOD LEVEL; BLOOD PRESSURE MEASUREMENT; BLOOD SAMPLING; BODY MASS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CROSSOVER PROCEDURE; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG MECHANISM; DRUG PROTEIN BINDING; DYSLIPIDEMIA; FAMILY HISTORY; GLUCOSE BLOOD LEVEL; HALF LIFE TIME; HUMAN; HYPERTENSION; IMMUNE RESPONSE; ISCHEMIC HEART DISEASE; LIPID ANALYSIS; MAJOR CLINICAL STUDY; OBESITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SMOKING; TREATMENT DURATION; CONTROLLED STUDY;

CHAPERONIN 60; DOUBLE-BLIND METHOD; DYSLIPIDEMIAS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; SIMVASTATIN;

EID: 79151476825     PISSN: 00099120     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2010.09.016     Document Type: Article

References (50)

1. Ghayour-Mobarhan M., Rahsepar A.A., Tavallaie S., Rahsepar S., Ferns G.A.A. Chapter 2: the potential role of heat shock proteins in cardiovascular disease. Evid In Vitro In Vivo Stud 2009, 48:27-72.
2. Lindquist S. The heat-shock response. Annu Rev Biochem 1986, 55:1151-1191.
3. Xu Q., Kiechl S., Mayr M., Metzler B., Egger G., Oberhollenzer F., et al. Association of serum antibodies to heat-shock protein 65 with carotid atherosclerosis: clinical significance determined in a follow-up study. Circulation 1999, 100:1169-1174.
4. Zhu J., Quyyumi A.A., Rott D., Csako G., Wu H., Halcox J., et al. Antibodies to human heat-shock protein 60 are associated with the presence and severity of coronary artery disease: evidence for an autoimmune component of atherogenesis. Circulation 2001, 103:1071-1075.
5. Buhlin K., Gustafsson A., Pockley A.G., Frostegard J., Klinge B. Risk factors for cardiovascular disease in patients with periodontitis. Eur Heart J 2003, 24:2099-2107.
6. Ghayour-Mobarhan M., Sahebkar A., Parizadeh S.M.R., Moohebati M., Tavallaie S., Kazemi-Bajestani S.M.R., et al. Antibody titres to heat shock protein 27 are elevated in patients with acute coronary syndrome. Int J Exp Pathol 2008, 89:209-215.
7. Xu Q., Schett G., Perschinka H., Mayr M., Egger G., Oberhollenzer F., et al. Serum soluble heat shock protein 60 is elevated in subjects with atherosclerosis in a general population. Circulation 2000, 102:14-20.
8. Ghayour-Mobarhan M., Lamb D.J., Tavallaie S., Ferns G.A. Relationship between plasma cholesterol, von Willebrand factor concentrations, extent of atherosclerosis and antibody titres to heat shock proteins-60, -65 and -70 in cholesterol-fed rabbits. Int J Exp Pathol 2007, 88:249-255.
9. Atar I., Gulmez O., Atar A., Bozbas H., Yildirir A., Ozin B., et al. The effects of prior beta-blocker therapy on serum C-reactive protein levels after percutaneous coronary intervention. Clin Cardiol 2005, 28:243-246.
10. Hurlimann J., Thorbecke G.J., Hochwald G.M. The liver as the site of C-reactive protein formation. J Exp Med 1966, 123:365-378.
11. Mackiewicz A., Speroff T., Ganapathi M.K., Kushner I. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 1991, 146:3032-3037.
12. Venugopal S.K., Devaraj S., Yuhanna I., Shaul P., Jialal I. Demonstration that C-reactive protein decreases eNOS expression and bioactivity in human aortic endothelial cells. Circulation 2002, 106:1439-1441.
13. de Ferranti S., Rifai N. C-reactive protein and cardiovascular disease: a review of risk prediction and interventions. Clin Chim Acta 2002, 317:1-15.
14. Burke A.P., Tracy R.P., Kolodgie F., Malcom G.T., Zieske A., Kutys R., et al. Elevated C-reactive protein values and atherosclerosis in sudden coronary death: association with different pathologies. Circulation 2002, 105:2019-2023.
15. Ridker P.M., Buring J.E., Shih J., Matias M., Hennekens C.H. Prospective study of C-reactive protein and the risk of future cardiovascular events among apparently healthy women. Circulation 1998, 98:731-733.
16. Ridker P.M., Cushman M., Stampfer M.J., Tracy R.P., Hennekens C.H. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
17. Tracy R.P., Lemaitre R.N., Psaty B.M., Ives D.G., Evans R.W., Cushman M., et al. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly. Results from the Cardiovascular Health Study and the Rural Health Promotion Project. Arterioscler Thromb Vasc Biol 1997, 17:1121-1127.
18. Thompson S.G., Kienast J., Pyke S.D., Haverkate F., van de Loo J.C. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635-641.
19. Ferreiros E.R., Boissonnet C.P., Pizarro R., Garcia Merletti P.F., Corrado G., Cagide A., et al. Independent prognostic value of elevated C-reactive protein in unstable angina. Circulation 1999, 100:1958-1963.
20. Ghayour-Mobarhan M., Lamb D.J., Vaidya N., Livingstone C., Wang T., Ferns G.A. Heat shock protein antibody titers are reduced by statin therapy in dyslipidemic subjects: a pilot study. Angiology 2005, 56:61-68.
21. Shepherd J., Cobbe S.M., Ford I., Isles C.G., Lorimer A.R., MacFarlane P.W., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995, 333:1301-1307.
22. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
23. Walter D.H., Dimmeler S., Zeiher A.M. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 2004, 4:385-393.
24. Wolfrum S., Jensen K.S., Liao J.K. Endothelium-dependent effects of statins. Arterioscler Thromb Vasc Biol 2003, 23:729-736.
25. Raggatt L.J., Partridge N.C. HMG-CoA reductase inhibitors as immunomodulators: potential use in transplant rejection. Drugs 2002, 62:2185-2191.
26. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium 2003, 10:43-47.
27. Ghayour-Mobarhan M., Lamb D.J., Lovell D.P., Livingstone C., Wang T., Ferns G.A. Plasma antibody titres to heat shock proteins-60, -65 and-70: their relationship to coronary risk factors in dyslipidaemic patients and healthy individuals. Scand J Clin Lab Investig 2005, 65:601-614.
28. Ferns G.A. Differential effects of statins on serum CRP levels: implications of recent clinical trials. Atherosclerosis 2003, 169:349-351.
29. Petkova S.B., Akilesh S., Sproule T.J., Christianson G.J., Al Khabbaz H., Brown A.C., et al. Enhanced half-life of genetically engineered human IgG1 antibodies in a humanized FcRn mouse model: potential application in humorally mediated autoimmune disease. Int Immunol 2006, 18:1759-1769.
30. Spiegelberg H.L., Weigle W.O. Studies on the catabolism of gamma-G subunits and chains. J Immunol 1965, 95:1034.
31. Spiegelberg H.L., Fishkin B.G. The catabolism of human G immunoglobulins of different heavy chain subclasses. 3. The catabolism of heavy chain disease proteins and of Fc fragments of myeloma proteins. Clin Exp Immunol 1972, 10:599.
32. Spiegelberg H.L. Biological role of different antibody classes. Int Arch Allergy Appl Immunol 1989, 90:S22.
33. Morell A., Terry W.D., Waldmann T.A. Metabolic properties of IgG subclasses in man. J Clin Invest 1970, 49:673.
34. Guisasola M.C., Dulin E., Almendral J., Garcia-Barreno P. Reduction of heat shock protein antibody levels by statin therapy. Lipids 2009, 44:317-324.
35. Shin Y.O., Bae J.S., Lee J.B., Kim J.K., Kim Y.J., Kim C., et al. Effect of cardiac rehabilitation and statin treatment on anti-HSP antibody titers in patients with coronary artery disease after percutaneous coronary intervention. Int Heart J 2006, 47:671-682.
36. Ortego M., Bustos C., Hernandez-Presa M.A., Tunon J., Diaz C., Hernandez G., et al. Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 1999, 147:253-261.
37. Wang T.D., Chen W.J., Lin J.W., Cheng C.C., Chen M.F., Lee Y.T. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. Atherosclerosis 2003, 170:315-323.
38. Mulhaupt F., Matter C.M., Kwak B.R., Pelli G., Veillard N.R., Burger F., et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003, 59:755-766.
39. Chow S.C. Immunomodulation by statins: mechanisms and potential impact on autoimmune diseases. Arch Immunol Ther Exp (Warsz) 2009, 57:243-251.
40. Takeda T., Hoshida S., Nishino M., Tanouchi J., Otsu K., Hori M. Relationship between effects of statins, aspirin and angiotensin II modulators on high-sensitive C-reactive protein levels. Atherosclerosis 2003, 169:155-158.
41. Strandberg T.E., Vanhanen H., Tikkanen M.J. Effect of statins on C-reactive protein in patients with coronary artery disease. Lancet 1999, 353:118-119.
42. Jialal I., Stein D., Balis D., Grundy S.M., ms-Huet B., Devaraj S. Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels. Circulation 2001, 103:1933-1935.
43. Prasad K. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 2006, 24:33-50.
44. Ridker P.M., Rifai N., Lowenthal S.P. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001, 103:1191-1193.
45. Albert M.A., Danielson E., Rifai N., Ridker P.M. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001, 286:64-70.
46. Ridker P.M., Rifai N., Pfeffer M.A., Sacks F., Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999, 100:230-235.
47. Genser B., Grammer T.B., Stojakovic T., Siekmeier R., Marz W. Effect of HMG CoA reductase inhibitors on low-density lipoprotein cholesterol and C-reactive protein: systematic review and meta-analysis. Int J Clin Pharmacol Ther 2008, 46:497-510.
48. Baigent C., Keech A., Kearney P.M., Blackwell L., Buck G., Pollicino C., et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins. Lancet 2005, 366:1267-1278.
49. Kaczmarek P., Sładek K., Skucha W., Rzeszutko M., Iwaniec T., Dziedzina S., et al. The influence of simvastatin on selected inflammatory markers in patients with chronic obstructive pulmonary disease. Pol Arch Med Wewn 2010, 120:11-18.
50. Matsumoto T., Fujita M., Sawamura T., Kakino A., Sato Y., Fujita Y., et al. Pitavastatin reduces lectin-like oxidized low-density lipoprotein receptor-1 ligands in hypercholesterolemic humans. Lipids 2010, 45:329-335.